MRNA241220C57000
- 0.01
- 0.000.00%
Moderna Newsroom
Weekly Buzz: It was a rough week just before the Winter Solstice
Catalyst Watch: Labor Pains for Amazon & Starbucks, Nasdaq Call-up for MicroStrategy and Pony AI Ratings
Friday Opens With Falling Prices, but Market Turns Around | Live Stock
Is Moderna Stock a Buy?
Moderna Options Spot-On: On December 19th, 214.79K Contracts Were Traded, With 705.56K Open Interest
Unusual Options Activity: SLB, Z and Others Attract Market Bets, SLB V/OI Ratio Reaches 375.0
Personalis Rallies Following $50 Million Investment From Merck, Extended Agreement With Moderna
Merck Buys $50 Million of Personalis Stock
Express News | Personalis Signs Multi-Year Extension With Moderna To Utilize Its ImmunoID NeXT Platform And Technology For V940/mRNA-4157
Express News | Personalis Inc: Merck Has Agreed to Purchase $50 Mln of Personalis Common Stock in a Private Placement at a Price of $3.56 per Share
Express News | Personalis Advances Business Strategy With Investment From Merck and Extends Collaboration With Moderna
Tesla, Bitcoin, S&P 500, Dow, Tank: Thanks a Lot FOMC | Wall Street Today
Express News | FOMC Cuts Interest Rates by 25 Basis Points, Sees Fewer Reductions Next Year
California Gov. Newsom Declares State of Emergency Over Bird Flu
Moderna Lowered to Hold at Argus Amid Lower COVID Vaccine Sales, Competitive RSV Market
Moderna Analyst Ratings
Dow Breaks Downward Spiral, with FOMC Rate Cut on Deck | Live Stock
Most Shorted S&P 500 Stocks in November
Argus Research Downgrades Moderna(MRNA.US) to Hold Rating
Moderna Options Spot-On: On December 17th, 62,777 Contracts Were Traded, With 694.1K Open Interest